Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation

Detalhes bibliográficos
Autor(a) principal: da Silva, Glenda Nicioli
Data de Publicação: 2018
Outros Autores: Filoni, Leandro Toshio, Salvadori, Maria Cecília, Salvadori, Daisy Maria Fávero [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1007/s12253-017-0255-x
http://hdl.handle.net/11449/178919
Resumo: Simultaneous use of cisplatin (CIS) and gemcitabine (GEN) for treating bladder cancer has increased because of their complementary effects. However, the molecular mechanisms underlying the activities of these two antineoplastic drugs are not fully known. Here, molecular biology techniques and microscopy were used to investigate transcriptomic and morphological changes in low and high-grade urinary bladder transitional carcinoma cell lines [RT4 - wild type TP53; 5637 - two TP53 mutations, one in codon 72 (Arg-Pro) and other in codon 280 (Arg-Thr) and T24 - in-frame deletion of tyrosine 126 in the TP53 allele] simultaneously treated with CIS/GEN. Gene expression profile was evaluated by PCR arrays; cell morphology by scanning and transmission electron microscopy, and apoptosis was analyzed using fluorescent dye. Results showed concomitantly upregulation of CDKN2B (G1/S transition), GADD45A (DNA repair and apoptosis) and SERTAD1 (regulation of transcription) gene, increased number of nuclear chamfers and apoptotic cells, and reduced number of microfilaments, organelles and in the size of the nucleus in 5637 and T24 cells after simultaneous treatment with CIS/GEN. In conclusion, independently of the TP53 mutation status and tumor grade, CIS/GEN induced gene modulation accompanied by changes in cell morphologies, which confirm the antiproliferative activity of the treatment protocol. These findings help to understand the pathways modulated by these antineoplastic agents and may provide insights for anti-cancer chemotherapy.
id UNSP_9c12152fc6c0a9579f74fbd7258465ad
oai_identifier_str oai:repositorio.unesp.br:11449/178919
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 MutationBladder cancerCell morphologyChemotherapyCisplatinGemcitabineGene expressionSimultaneous use of cisplatin (CIS) and gemcitabine (GEN) for treating bladder cancer has increased because of their complementary effects. However, the molecular mechanisms underlying the activities of these two antineoplastic drugs are not fully known. Here, molecular biology techniques and microscopy were used to investigate transcriptomic and morphological changes in low and high-grade urinary bladder transitional carcinoma cell lines [RT4 - wild type TP53; 5637 - two TP53 mutations, one in codon 72 (Arg-Pro) and other in codon 280 (Arg-Thr) and T24 - in-frame deletion of tyrosine 126 in the TP53 allele] simultaneously treated with CIS/GEN. Gene expression profile was evaluated by PCR arrays; cell morphology by scanning and transmission electron microscopy, and apoptosis was analyzed using fluorescent dye. Results showed concomitantly upregulation of CDKN2B (G1/S transition), GADD45A (DNA repair and apoptosis) and SERTAD1 (regulation of transcription) gene, increased number of nuclear chamfers and apoptotic cells, and reduced number of microfilaments, organelles and in the size of the nucleus in 5637 and T24 cells after simultaneous treatment with CIS/GEN. In conclusion, independently of the TP53 mutation status and tumor grade, CIS/GEN induced gene modulation accompanied by changes in cell morphologies, which confirm the antiproliferative activity of the treatment protocol. These findings help to understand the pathways modulated by these antineoplastic agents and may provide insights for anti-cancer chemotherapy.School of Pharmacy UFOP – Federal University of Ouro PretoEscola de Farmácia Departamento de Análises Clínicas UFOP – Universidade Federal de Ouro PretoInstitute of Physics USP – University of São PauloMedical School UNESP – State University of São PauloMedical School UNESP – State University of São PauloUFOP – Federal University of Ouro PretoUFOP – Universidade Federal de Ouro PretoUniversidade de São Paulo (USP)Universidade Estadual Paulista (Unesp)da Silva, Glenda NicioliFiloni, Leandro ToshioSalvadori, Maria CecíliaSalvadori, Daisy Maria Fávero [UNESP]2018-12-11T17:32:42Z2018-12-11T17:32:42Z2018-04-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article407-417application/pdfhttp://dx.doi.org/10.1007/s12253-017-0255-xPathology and Oncology Research, v. 24, n. 2, p. 407-417, 2018.1532-28071219-4956http://hdl.handle.net/11449/17891910.1007/s12253-017-0255-x2-s2.0-850200642312-s2.0-85020064231.pdfScopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengPathology and Oncology Research0,751info:eu-repo/semantics/openAccess2023-11-11T06:12:27Zoai:repositorio.unesp.br:11449/178919Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462023-11-11T06:12:27Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation
title Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation
spellingShingle Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation
da Silva, Glenda Nicioli
Bladder cancer
Cell morphology
Chemotherapy
Cisplatin
Gemcitabine
Gene expression
title_short Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation
title_full Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation
title_fullStr Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation
title_full_unstemmed Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation
title_sort Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation
author da Silva, Glenda Nicioli
author_facet da Silva, Glenda Nicioli
Filoni, Leandro Toshio
Salvadori, Maria Cecília
Salvadori, Daisy Maria Fávero [UNESP]
author_role author
author2 Filoni, Leandro Toshio
Salvadori, Maria Cecília
Salvadori, Daisy Maria Fávero [UNESP]
author2_role author
author
author
dc.contributor.none.fl_str_mv UFOP – Federal University of Ouro Preto
UFOP – Universidade Federal de Ouro Preto
Universidade de São Paulo (USP)
Universidade Estadual Paulista (Unesp)
dc.contributor.author.fl_str_mv da Silva, Glenda Nicioli
Filoni, Leandro Toshio
Salvadori, Maria Cecília
Salvadori, Daisy Maria Fávero [UNESP]
dc.subject.por.fl_str_mv Bladder cancer
Cell morphology
Chemotherapy
Cisplatin
Gemcitabine
Gene expression
topic Bladder cancer
Cell morphology
Chemotherapy
Cisplatin
Gemcitabine
Gene expression
description Simultaneous use of cisplatin (CIS) and gemcitabine (GEN) for treating bladder cancer has increased because of their complementary effects. However, the molecular mechanisms underlying the activities of these two antineoplastic drugs are not fully known. Here, molecular biology techniques and microscopy were used to investigate transcriptomic and morphological changes in low and high-grade urinary bladder transitional carcinoma cell lines [RT4 - wild type TP53; 5637 - two TP53 mutations, one in codon 72 (Arg-Pro) and other in codon 280 (Arg-Thr) and T24 - in-frame deletion of tyrosine 126 in the TP53 allele] simultaneously treated with CIS/GEN. Gene expression profile was evaluated by PCR arrays; cell morphology by scanning and transmission electron microscopy, and apoptosis was analyzed using fluorescent dye. Results showed concomitantly upregulation of CDKN2B (G1/S transition), GADD45A (DNA repair and apoptosis) and SERTAD1 (regulation of transcription) gene, increased number of nuclear chamfers and apoptotic cells, and reduced number of microfilaments, organelles and in the size of the nucleus in 5637 and T24 cells after simultaneous treatment with CIS/GEN. In conclusion, independently of the TP53 mutation status and tumor grade, CIS/GEN induced gene modulation accompanied by changes in cell morphologies, which confirm the antiproliferative activity of the treatment protocol. These findings help to understand the pathways modulated by these antineoplastic agents and may provide insights for anti-cancer chemotherapy.
publishDate 2018
dc.date.none.fl_str_mv 2018-12-11T17:32:42Z
2018-12-11T17:32:42Z
2018-04-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1007/s12253-017-0255-x
Pathology and Oncology Research, v. 24, n. 2, p. 407-417, 2018.
1532-2807
1219-4956
http://hdl.handle.net/11449/178919
10.1007/s12253-017-0255-x
2-s2.0-85020064231
2-s2.0-85020064231.pdf
url http://dx.doi.org/10.1007/s12253-017-0255-x
http://hdl.handle.net/11449/178919
identifier_str_mv Pathology and Oncology Research, v. 24, n. 2, p. 407-417, 2018.
1532-2807
1219-4956
10.1007/s12253-017-0255-x
2-s2.0-85020064231
2-s2.0-85020064231.pdf
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Pathology and Oncology Research
0,751
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 407-417
application/pdf
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1803046428544598016